Edit the message. Rewrite the future.
Editing a single letter on RNA to repair or form a de novo protein with enhanced functionality. Our mission is to deliver the promise of genetic medicines for rare and prevalent diseases.
Our science
Our approach to edit RNA involves redirecting a naturally occurring editing process that’s inside every cell in the human body. This is accomplished by delivering a chemically modified RNA that helps to target precisely the change we want to make. Our proprietary platform called Oligonucleotide Promoted Editing of RNA (OPERA®) enables us to discover and develop these drug candidates.
KRRO-121
Our lead program, KRRO-121, is a GalNAc-conjugated RNA editing oligonucleotide for the potential treatment of hyperammonemia in patients with UCDs of any mutational background as well as patients with HE. Utilizing Korro’s proprietary OPERA® platform, KRRO-121 is designed to generate a stabilized, de novo glutamine synthetase (GS) protein, a critical enzyme involved in ammonia clearance.
Our pipeline
Our pipeline programs demonstrate the versatility of our approach in bringing precision and tunability to genetic medicines to address a broad range of rare and highly prevalent diseases.
News and media
Career Opportunities
Write the next chapter of your career with Korro, where we are developing a novel class of medicines.